
A rare type of leukemia called acute dendritic leukemia has the worst prognosis and is very difficult to treat.
Juan Cruz Cigudosa's team, from the Spanish National Cancer Research Centre's (CNIO) Molecular Cytogenetics Group, has for the first time sequenced the exome -the coding, or protein-generating, regions of the genome— of dendritic cell leukaemia.
Advertisement
The analyses, published in Leukemia, the world's leading journal in onco- haematology, uncover new genetic pathways that could revolutionise treatment guidelines for these patients.
'EPIGENETIC' GENES ARE ALTERED IN MOST CASES
For the first time in human leukaemias, scientists have described mutations in four genes (IKZF3, HOXB9, UBE2G2 and ZEB2) that have important cellular functions, such as gene regulation and cellular differentiation.
"In addition to these genes, we have found that more than half of the cases harbour mutations in epigenetic genes at diagnosis —those genes that introduce chemical modifications in the DNA— something that had never been observed in this type of leukaemia", says Cigudosa. "Therapies directed against these epigenetic genes already exist, so these patients could also benefit from them".
In summary, the genetic profile of acute dendritic cell leukaemia, currently treated as a lymphoid leukaemia, is similar to that of myeloid leukaemia. "These results suggests a change in the treatment guidelines for these patients, who were completely misplaced", says Juliane Menezes, the first author of the study.
According to Cigudosa, "this study is a clear example of the role of genomics in translational research being carried out by Spanish scientists, in general, and more specifically at CNIO".
To carry out this work, the authors analysed the exome of three patients diagnosed with dendritic cell leukaemia and validated the results using a panel of 38 genes and 25 additional patients (known as a targeted resequencing strategy), coming from 9 Spanish hospitals.
Source: Eurekalert
For the first time in human leukaemias, scientists have described mutations in four genes (IKZF3, HOXB9, UBE2G2 and ZEB2) that have important cellular functions, such as gene regulation and cellular differentiation.
Advertisement
"In addition to these genes, we have found that more than half of the cases harbour mutations in epigenetic genes at diagnosis —those genes that introduce chemical modifications in the DNA— something that had never been observed in this type of leukaemia", says Cigudosa. "Therapies directed against these epigenetic genes already exist, so these patients could also benefit from them".
In summary, the genetic profile of acute dendritic cell leukaemia, currently treated as a lymphoid leukaemia, is similar to that of myeloid leukaemia. "These results suggests a change in the treatment guidelines for these patients, who were completely misplaced", says Juliane Menezes, the first author of the study.
According to Cigudosa, "this study is a clear example of the role of genomics in translational research being carried out by Spanish scientists, in general, and more specifically at CNIO".
To carry out this work, the authors analysed the exome of three patients diagnosed with dendritic cell leukaemia and validated the results using a panel of 38 genes and 25 additional patients (known as a targeted resequencing strategy), coming from 9 Spanish hospitals.
Source: Eurekalert
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Genetics & Stem Cells News

Can stem cell therapy cure fistula? Yes, treatment with stem cells has had a success rate when used in perianal fistulas due to Crohn's Disease.

In zebrafish models of SURF1 mitochondrial disease, scientists have discovered drugs to prevent neurological decompensation.

New study advances intravitreal gene therapy platform to develop safe and effective therapies for visual loss in Usher Syndrome, rare disorder.

The study experiments shed light on a rare example of how autism-associated mutation could altered nuclear dynamics.

A genotype-first approach to patient care involves selecting patients with specific genomic variants and then studying their traits and symptoms.